Try
ABBOTT LABORATORIES
ABTUnited States
77 filed reports · 477 financial concepts · 41 earnings calls · 8 media appearances
Filed reports
77 reports · Jun 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 12 operating metrics, 196 guidance figures, 116 commentary passages.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Current · 8-KSEC EDGAR | 34 | 182 | Jun 2018 to Jun 2026 |
| Quarterly · 10-QSEC EDGAR | 32 | 6,711 | Jun 2016 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 11 | 6,376 | Dec 2016 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Jul 28, 2026 | 479 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Jul 16, 2026 | 5 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Jul 16, 2026 | 6 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | Apr 29, 2026 | 13 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | Apr 29, 2026 | 352 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | Apr 16, 2026 | 5 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | Apr 16, 2026 | 6 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 20, 2026 | 1,315 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 20, 2026 | 13 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Jan 22, 2026 | 6 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 29, 2025 | 368 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Oct 15, 2025 | 4 | Open |
Financial data
477 concepts · 13,269 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial444 concepts · 9,040 facts · Dec 2014 to Jun 2026
- Cash and cash equivalents at carrying value58 · Dec 2014 to Jun 2026
- Net income loss58 · Dec 2014 to Jun 2026
- Revenue58 · Dec 2014 to Jun 2026
- Comprehensive income net of tax57 · Dec 2014 to Jun 2026
- Costs and expenses57 · Dec 2014 to Jun 2026
- Foreign currency transaction gain loss before tax57 · Dec 2014 to Jun 2026
- Income tax expense benefit57 · Dec 2014 to Jun 2026
- Incremental common shares attributable to share based payment arrangements57 · Dec 2014 to Jun 2026
- Investment income interest57 · Dec 2014 to Jun 2026
- Net income loss available to common stockholders basic57 · Dec 2014 to Jun 2026
- Operating income loss57 · Dec 2014 to Jun 2026
- Other comprehensive income loss net of tax portion attributable to parent57 · Dec 2014 to Jun 2026
- Other comprehensive income loss pension and other postretirement benefit plans tax57 · Dec 2014 to Jun 2026
- Other nonoperating income expense57 · Dec 2014 to Jun 2026
- Selling general and administrative expense57 · Dec 2014 to Jun 2026
- Depreciation56 · Dec 2014 to Jun 2026
- Increase decrease in accounts receivable56 · Dec 2014 to Jun 2026
- Increase decrease in inventories56 · Dec 2014 to Jun 2026
- Net cash provided by used in financing activities56 · Dec 2014 to Jun 2026
- Net cash provided by used in investing activities56 · Dec 2014 to Jun 2026
- Net cash provided by used in operating activities56 · Dec 2014 to Jun 2026
- Payments for proceeds from other investing activities56 · Dec 2014 to Jun 2026
- Payments for repurchase of common stock56 · Dec 2014 to Jun 2026
- Payments to acquire property plant and equipment56 · Dec 2014 to Jun 2026
Segment20 concepts · 3,798 facts · Dec 2014 to Jun 2026
- Revenue2,906 · Dec 2014 to Jun 2026
- Operating income loss233 · Dec 2014 to Jun 2026
- Goodwill156 · Jun 2016 to Mar 2026
- Depreciation98 · Dec 2014 to Jun 2026
- Total Assets73 · Dec 2015 to Mar 2026
- Segment expenditure addition to long lived assets60 · Dec 2021 to Jun 2026
- Cost of goods and services sold (US GAAP)56 · Dec 2022 to Jun 2026
- Research and development expense56 · Dec 2022 to Jun 2026
- Selling general and administrative expense56 · Dec 2022 to Jun 2026
- Property plant and equipment additions29 · Dec 2017 to Dec 2022
- Payments to acquire property plant and equipment20 · Dec 2015 to Dec 2018
- Impairment of intangible assets indefinitelived excluding goodwill17 · Mar 2016 to Dec 2024
- Payments to acquire productive assets15 · Dec 2014 to Dec 2016
- Impairment of intangible assets finitelived7 · Sep 2020 to Dec 2024
- Revenue (excluding assessed tax)6 · Dec 2019 to Dec 2021
- Inventory recall expense3 · Mar 2022 to Sep 2022
- Disposal group not discontinued operation gain loss on disposal2 · Jun 2024 to Dec 2024
- Established Pharmaceuticals2 · Jun 2024 to Dec 2024
- Indefinite lived intangible assets period increase decrease2 · Dec 2024 to Dec 2025
- Revenue from contracts with customers (excluding tax)1 · Dec 2017
Geography5 concepts · 249 facts · Dec 2014 to Jun 2026
- Revenue238 · Dec 2014 to Jun 2026
- Foreign currency transaction loss before tax6 · Mar 2016 to Dec 2016
- Effect of exchange rate on cash and cash equivalents3 · Mar 2016 to Sep 2016
- Unrecognized tax benefits increases resulting from prior period tax positions1 · Dec 2021
- Venezuela1 · Sep 2016
Guidance7 concepts · 172 facts · Jul 2018 to Jul 2026
- EPS (Diluted) Guidance90 · Jul 2018 to Jul 2026
- EPS (Diluted) Guidance (Adjusted (non-GAAP))44 · Jul 2018 to Apr 2024
- Revenue Growth Guidance22 · Jan 2023 to Jul 2026
- Revenue Growth Guidance (Organic)8 · Jan 2019 to Apr 2024
- Operating Margin Guidance6 · Jan 2025 to Jul 2025
- EPS (Diluted) Growth Guidance1 · Jan 2021
- EPS (Diluted) Growth Guidance (Adjusted (non-GAAP))1 · Jan 2021
KPI1 concepts · 10 facts · Mar 2026 to Jun 2026
- Comparable Sales Growth10 · Mar 2026 to Jun 2026
Segments
4,047 factsFigures broken down by business line, region, product or another axis the company reports on.
Subsegments20 members · 2,206 facts
- Electrophysiology158 · Mar 2017 to Jun 2026
- Heart Failure158 · Mar 2017 to Jun 2026
- Neuromodulation158 · Mar 2017 to Jun 2026
- Rhythm Management158 · Mar 2017 to Jun 2026
- Structural Heart158 · Mar 2017 to Jun 2026
- Adult Nutritionals143 · Mar 2017 to Jun 2026
- Core Laboratory143 · Mar 2017 to Jun 2026
- Pediatric Nutritionals143 · Mar 2017 to Jun 2026
- Molecular137 · Mar 2017 to Dec 2025
- Point Of Care137 · Mar 2017 to Dec 2025
- Rapid Diagnostics125 · Dec 2017 to Dec 2025
- Key Emerging Markets122 · Mar 2017 to Jun 2026
- Diabetes Care117 · Dec 2017 to Jun 2026
- Other Emerging Markets81 · Dec 2020 to Jun 2026
- Vascular78 · Dec 2020 to Jun 2026
- Other68 · Mar 2017 to Mar 2022
- Cardiovascular And Neuromodulation Products57 · Dec 2017 to Jun 2022
- Vascular Products41 · Mar 2017 to Sep 2019
- Cancer Diagnostics12 · Mar 2025 to Jun 2026
- Rapid And Molecular12 · Mar 2025 to Jun 2026
Statement business segments14 members · 1,592 facts
- Diagnostic Products319 · Dec 2014 to Jun 2026
- Nutritional Products305 · Dec 2014 to Jun 2026
- Established Pharmaceutical Products288 · Dec 2014 to Jun 2026
- Medical Devices255 · Dec 2017 to Jun 2026
- All Other Segments97 · Dec 2014 to Mar 2022
- Cardiovascular And Neuromodulation Products87 · Dec 2014 to Sep 2019
- Diagnostic products56 · Dec 2015 to Mar 2026
- Established pharmaceutical products56 · Dec 2015 to Mar 2026
- Nutritional products56 · Dec 2015 to Mar 2026
- Medical devices39 · Dec 2018 to Mar 2026
- Cardiovascular and neuromodulation products19 · Dec 2015 to Sep 2019
- All other segments6 · Dec 2019 to Dec 2021
- Non Reportable5 · Mar 2016 to Dec 2016
- Non reportable segment4 · Dec 2015 to Dec 2018
Statement geographicalsrt:StatementGeographicalAxis13 members · 173 facts
- Non Us47 · Jun 2017 to Jun 2026
- US47 · Dec 2016 to Jun 2026
- CH10 · Dec 2016 to Dec 2025
- CN10 · Dec 2016 to Dec 2025
- DE10 · Dec 2016 to Dec 2025
- IN10 · Dec 2016 to Dec 2025
- JP10 · Dec 2016 to Dec 2025
- NL9 · Dec 2016 to Dec 2024
- All Other Countries6 · Dec 2020 to Dec 2025
- Other Countries6 · Dec 2016 to Dec 2021
- CA4 · Dec 2019 to Dec 2022
- GB3 · Dec 2023 to Dec 2025
- VE1 · Dec 2016
Statement geographicalus-gaap:StatementGeographicalAxis18 members · 76 facts
- VE9 · Mar 2016 to Dec 2016
- US6 · Dec 2014 to Mar 2018
- BR4 · Dec 2014 to Dec 2017
- CA4 · Dec 2014 to Dec 2017
- CH4 · Dec 2014 to Dec 2017
- CN4 · Dec 2014 to Dec 2017
- CO4 · Dec 2014 to Dec 2017
- DE4 · Dec 2014 to Dec 2017
- GB4 · Dec 2014 to Dec 2017
- IN4 · Dec 2014 to Dec 2017
- IT4 · Dec 2014 to Dec 2017
- JP4 · Dec 2014 to Dec 2017
- NL4 · Dec 2014 to Dec 2017
- Other Countries4 · Dec 2014 to Dec 2017
- RU4 · Dec 2014 to Dec 2017
- VN4 · Dec 2014 to Dec 2017
- FR3 · Dec 2015 to Dec 2017
- Non Us2 · Mar 2017 to Mar 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary105 claims from 8 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary240 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes5 claims from 1 reports · Dec 2025
- Risk factors39 risks from 2 annual reports · 2024 to 2025
Earnings calls
41 calls · Jul 2016 to Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 16, 2026
- FY2026 Q1Apr 16, 2026
- FY2025 Q4Jan 22, 2026
- FY2025 Q3Oct 15, 2025
- FY2025 Q2Jul 17, 2025
- FY2025 Q1Apr 16, 2025
- FY2024 Q4Jan 22, 2025
- FY2024 Q3Oct 16, 2024
- FY2024 Q2Jul 18, 2024
- FY2024 Q1Apr 17, 2024
- FY2023 Q4Jan 23, 2024
- FY2023 Q3Oct 17, 2023
- FY2023 Q2Jul 19, 2023
- FY2023 Q1Apr 18, 2023
- FY2022 Q4Jan 24, 2023
- FY2022 Q3Oct 18, 2022
Executive media
8 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- Other appearances4 · Mar 2021 to Aug 2025
- TV interviews4 · Oct 2021 to Jul 2025
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.